Compound Properties and Drug Quality

The Practice of Medicinal Chemistry

Volumn , Issue , 2008, Pages 481-490

  Lipinski, Christopher A ^a  

^a Melior Discovery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877738654     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374194-3.00022-6     Document Type: Chapter

References (16)

1. Leeson P.D., Davis A.M. Time-related differences in the physical property profiles of oral drugs. J. Med. Chem. 2004, 47:6338-6448.
2. Blake J.F. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med. Chem. 2005, 1:649-655.
3. Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 2006, 49:2969-2978.
4. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
5. Leach, A. R., Hann, M. M., Burrows, J. N., Griffen, E. J. Fragment screening: an introduction. In Structure-Based Drug Discovery, 2006, pp. 142-172.
6. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6(3):211-219.
7. Bergström C.A.S., Wassvik C.M., Johansson K., Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J. Med. Chem. 2007, ACS ASAP.
8. Avdeef A. Solubility of sparingly-soluble ionizable drugs. Adv. Drug Deliv. Rev. 2007, 59(7):568-590.
9. Singhal D., Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 2004, 56(3):335-347.
10. Oldenburg K., Pooler D., Scudder K., Lipinski C., Kelly M. High throughput sonication: evaluation for compound solubilization. Combin. Chem. High Throughput Screening 2005, 8:499-512.
11. Murray C.W., Verdonk M.L. The consequences of translational and rotational entropy lost by small molecules on binding to proteins. J. Comput.-Aided Mol. Des. 2002, 16(10):741-753.
12. Leeson P.D., Davis A.M., Steele J. Drug-like properties: guiding principles for design - or chemical prejudice?. Drug Discov. Today Tech. 2004, 1(3):189-195.
13. Oprea T.I., Allu T.K., Fara D.C., Rad R.F., Ostopovici L., Bologa C.G. Lead-like, drug-like or "pub-like": How different are they?. J. Comput.-Aided Mol. Des. 2007, 21(1-3):113-119.
14. Hopkins A.L., Groom C.R., Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 2004, 9(10):430-431.
15. Cruciani G., Carosati E., De Boeck B., Ethirajulu K., Mackie C., Howe T., Vianello R. MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. 2005, 48(22):6970-6979.
16. Lennernäs, H., Abrahamsson, B. The biopharmaceutics classification system. In Comprehensive Medicinal Chemistry II, Vol. 5, 2007, pp. 971-988.